Off-target screens: When no result is the winning outcome!
A recent LinkedIn post discusses how the specificity of the screening tool is a key consideration when investigating potential off-target receptor binding:
“Adverse effects that are triggered when a drug binds to a receptor other than its primary target can be a serious threat to the clinical success of a drug candidate. Not only might adverse events jeopardise millions of dollars already spent on R&D but they potentially put clinical trial participants at risk of serious harm. Whilst it would seem intuitive to confirm target specificity and screen for off-targets as early as possible in development, in reality, managing risk is only achievable when results from early safety studies are both meaningful and reliable….”